key: cord-1053224-lqjvxm3w authors: Zheng, Lu; Zhang, Lina; Huang, Jiamin; Nandakumar, Kutty Selva; Liu, Shuwen; Cheng, Kui title: Potential treatment methods targeting 2019-nCoV infection date: 2020-07-28 journal: Eur J Med Chem DOI: 10.1016/j.ejmech.2020.112687 sha: b612ac8dd43c78adc0b47d5087216d1029195104 doc_id: 1053224 cord_uid: lqjvxm3w The novel coronavirus, 2019-nCoV, has quickly spread across the world and pose serious threat to public health because it can infect people very easily. The major clinical symptoms of 2019-nCoV infection include fever, dry cough, myalgia, fatigue, and diarrhea. The 2019-nCoV belongs to the betacoronavirus family, and gene sequencing results demonstrate that it is a single-stranded RNA virus, closely related to Severe Acute Respiratory Syndrome CoV (SARS-CoV) and Middle East Respiratory Syndrome CoV (MERS-CoV). It has been observed that the virus invades human body mainly through binding to angiotensin-converting enzyme 2 (ACE2) receptors similar to SARS-CoV and the main protease (Mpro) acts as a critical protease for digesting the polyprotein into functional polypeptides during the replication and transcription process of 2019-nCoV. In this review, we summarized the real-time information of 2019-nCoV treatment methods and mainly focused on the chemical drugs including lopinavir/ritonavir, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir and other potential innovative active molecules. Their potential targets, activity, clinical status and side effects are described. In addition, Traditional Chinese Medicine (TCM), Convalescent plasma therapy (CPT) and biological reagents available, as well as the promising vaccine candidates against 2019-nCoV are also discussed. Since December 2019, the novel coronavirus (2019-nCoV, SARS-CoV-2, COVID-19) causes an 2 epidemic of acute respiratory syndrome and has rapidly become a worldwide threat to public 3 health. As of 15 July 2020, at least 13,691,570 cases and 586,820 deaths were identified around 4 the world. The major clinical symptoms of 2019-nCoV infection include fever, dry cough, short of 5 breath, chest pain, fatigue, and diarrhea. 1 Although few patients were identified without any 6 abnormal radiological findings. 2 Many severe patients have also developed dyspnea and 7 lymphopenia. However, until now no specific medicine is identified that could efficiently control 8 or eliminate the virus. On 22 Feb 2020, researchers have successfully isolated the 2019-nCoV and 9 sequenced its gene. The results showed that 2019-nCoV belongs to betacoronavirus with a 10 single-stranded RNA, 3 which is closely related to severe acute respiratory syndrome CoV 11 (SARS-CoV) and Middle East respiratory syndrome Cov (MERS-CoV). 4 Therefore the clinical 12 experiences gained against SARS and MERS provide possible ways to treat 2019-nCoV infection 13 effectively. SARS-CoV-2 encodes at least 27 proteins, including 15 non-structural proteins, 4 major 14 structural proteins, and 8 auxiliary proteins. 5 The 4 major structural proteins are the spike (S), 15 membrane (M), envelope (E) and the nucleocapsid (N) proteins, with the S protein mainly 16 affecting the fusion and cell entry process of the virus, the M protein mainly defines the shape of 17 the viral envelope, and both the E and N proteins are actively participating in the viral assembly 18 and budding events. 6 Angiotensin-converting enzyme 2 (ACE2) is the receptor of SARS-CoV-2, 19 and the S protein primed by the cellular serine protease TMPRSS2 might facilitate the entry 20 process of the virus into the host cells. Therefore, the serine protease TMPRSS2 inhibitor 21 camostat mesylate (Table 1 ) might prevent the entry of SARS-CoV-2 into cells. 7 With the 22 imminent threat of the virus growing exponentially, it is high priority to develop specific vaccines 23 and drugs to combat COVID-19 infection. Fortunately, experimental vaccines are promising, while, 24 the clinical trials of small chemical molecules showed certain beneficial effects. Currently, many 25 medications and drugs are being used in clinics worldwide to test their effectiveness including 26 lopinavir/ritonavir, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir and 27 Traditional Chinese Medicine (TCM). Besides, scientists are exploring several specific molecules 28 and combinations of different drugs to treat the patients having SARS-CoV-2 infection. In this 29 review, we collected and sorted out the relevant information available currently to combat 30 SARS-CoV-2 and we mainly focused on the chemical drugs (Table 1) . At the same time, we have 31 also discussed the biological methods including convalescent plasma therapy (CPT) and the 32 promising vaccines under development against 2019-nCoV. 33 34 35 2. Chemical drugs 36 Many chemical drugs have shown promising antiviral activities against SARS-CoV-2. Here we 37 summarized their chemical structures, effects, targets and severe adverse effects in Table 1 . In 38 addition, their possible mode of action against 2019-nCoV is depicted in Fig. 1 3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide (Table 1). It is the active component of this drug 3 combination, which blocks the division of Gag-Pol polyproteins resulting in the production of 4 immature virus particles incapable of infecting the patients further. However, LPV has no effect 5 on cells having integrated viral DNA, and only prevents subsequent infections of other susceptible 6 cells. Pharmacokinetic studies have demonstrated that lopinavir is mainly metabolized by CYP3A4 7 and produces low systemic concentrations when used alone. However, the metabolism of 8 lopinavir could be inhibited by ritonavir. Hence, a combination of these two drugs could prolong 9 the systemic exposure to lopinavir and keep the lopinavir concentration in the circulation for a 10 longer period of time. The recommended dose for adults is 400/100 mg twice daily. The most 11 common adverse effects in adults associated with LPV/r medication are diarrhoea and other 12 gastrointestinal disturbances, asthenia, headache and skin rashes. 8 Based on the Diagnosis and 13 Treatment Guidelines of the 2019-nCoV in China (the seventh edition), LPV/r is included for 14 treating the coronavirus pneumonia, however its efficacy and safety remains to be established 15 clearly. Antiviral effects of lopinavir at EC 50 value of 26.1 μM but not ritonavir against SARS-CoV- 2 16 in vitro was reported earlier (Table 1) . 9 Later in a clinical trial, 47 patients with COVID- 19 17 infection, admitted to Rui'an People's Hospital, were tested along with a control group with LPV/r. 18 This combination treatment with LPV/r had a more clearly therapeutic effect in lowering the body 19 temperature and restoring homeostasis with no obvious toxic and side effects. 10 However, a 20 paper published in the New England Journal of Medicine pointed out that LPV/r treatment did 21 not significantly accelerate the clinical improvement and reduced mortality in patients with 22 serious COVID-19. 11 Recently, a clinical trial (NCT04321174) is recruiting participants to further 23 evaluate the efficacy of LPV/r for treating Covid-19 patients (Table 2 ). 24 25 Chloroquine phosphate is a water-soluble compound with the chemical structure of 27 7-chloro-4-((4'-diethylamino-1-methylbutyl)amino)quinolinediphosphate (Table 1) , which is 28 widely used for treating malarial infection and autoimmune diseases, like lupus (both discoid 29 lupus erythematosus and systemic lupus erythematosus) and arthritis. It is one of the first-line 30 disease-modifying anti-rheumatic drugs used for treating rheumatoid arthritis (RA) and it acts by 31 inhibiting antigen presentation capacity of dendritic cells, cytokine production in macrophages, 32 as well as calcium and Toll-like receptor (TLR) signaling in B, T and other immune cells. 12 Later, 33 studies also discovered the broad-spectrum virus-resistance activity of chloroquine (CQ). 34 Chloroquine is mainly absorbed from the gastrointestinal tract, and it might block the virus 35 infection by increasing the endosomal pH required for virus/cell fusion, as well as by interfering 36 with the glycosylation of cellular receptors of SARS-CoV. 13 An article in Cell Research reported 37 that CQ could prevent 2019-nCoV infection at the cellular level (EC 50 = 1.13 μM, CC 50 > 100 μM, SI > 38 88.50) ( Table 1) . Immunofluorescence studies on virus infection after chloroquine treatment also 39 proved the anti-2019-nCoV activity of CQ (Fig. 2 ). 14 Subsequently, the clinical studies confirmed 40 its effectiveness against 2019-nCoV at a dose of 500 mg/day with no obvious serious adverse 41 reactions. 15 Although patients showed few adverse effects in the clinics at the standard dose of 42 chloroquine, the main severe side effects include retinopathy, cardiomyopathy and 43 neuromyopathy, while used for longer periods, and the acute toxicity of chloroquine occurred 44 when high dose was rapidly administered by parenteral routes. 12 Therefore clinicians should 1 closely observe adverse reactions with chloroquine treatment, especially with elderly patients. 2 Recently, many clinical trials with chloroquine against 2019-nCoV were initiated in many health 3 care centers (Table 2 ). 4 5 Hydroxychloroquine (HCQ) is an aminoquinoline compound modified by chloroquine, with an 7 N-hydroxyethyl side chain instead of the N-diethyl group of chloroquine. An increase in hydroxyl 8 moiety makes it highly water soluble and less toxic than chloroquine, while still retaining the 9 antiviral activity. The immunomodulatory mechanisms are similar to chloroquine by elevating the 10 pH through accumulation in lysosomes. Thus, HCQ interferes in the process of antigen 11 presentation (Fig. 1) and possibly attenuating the inflammatory response by significantly 12 decreasing the production of pro-inflammatory factors in COVID-19 patients. Similar to CQ, HCQ 13 has beneficial effects in immunodeficient conditions and also reduces development of metabolic 14 and cardiovascular complications apart from having anti-tumor and anti-thrombotic effects. 12 15 HCQ with a EC 50 of 0.72 μM was reported to have anti-viral activity against COVID-19 in vitro, 16 which suggested the potential use of HCQ in clinics. 16 Results from an open label 17 non-randomized clinical trial of limited size in France claimed HCQ (200 mg, three times per day 18 in 10 days) used in COVID-19 patients might be efficient in clearing nasopharyngeal carriage of 19 SARS-CoV-2 within three to six days. A combination of HCQ and azithromycin also 20 showed synergistic effect providing an alternate treatment strategy for SARS-CoV-2 infection. 17 21 However, at present there is still no clear evidence to support the effectiveness of HCQ against 22 SARS-CoV-2 infection, 18 which remains to be confirmed by clinical trials (Table 2 ). Although HCQ 23 is a less toxic molecule, poisoning occurs with its prolonged use and over-dosage, particularly 24 irreversible retinopathy possibly leading to loss of vision. Therefore, clinical monitoring and early 25 recognition of toxic symptoms are essential for an effective management strategy. Clinicians 26 should monitor the dose taken by the patients and pay close attention to the side effects 27 including retinal toxicity, neuromyopathy, and cardiac disease during clinical trials. 28 29 Arbidol (ARB), also known as umifenovir, is recommended as a specific anti-influenza drug to 31 control influenza A and influenza B viral infections. It has been approved in Russia and China for 32 human use, with no major adverse effects reported to date. It prevents contact between the 33 virus and host cells and penetration of virus particles into the cell by inhibiting the fusion of the 34 virus lipid shell to the cell membrane ( Fig. 1 ). 19 ARB is an indole analogue and, the amine in 35 position 4 and the hydroxyl moiety in position 5 are important for the antiviral action of ARB. 36 Insertion of a methyl group between the indole ring and 5-hydroxyl group has considerably 37 increased its antiviral potency, whereas introduction of particular azote-based heterocyclic 38 groups at position 4 improved anti-HBV activity. Replacement of the S-phenyl group at position 2 39 by a phenyl-sulfonyl group decreased its cytotoxicity, while increasing the anti-HBV activity of the 40 compound. 20 Interestingly, arbidol has substantial antiviral activities against Zika virus (ZIKV), 41 West Nile virus (WNV) and Tick-borne encephalitis virus (TBEV) with EC 50 values ranging from 42 10.57 ± 0.74 to 19.16 ± 0.29 µM in HBCA and Vero cells. 21 It also has antiviral potential against 43 herpes viruses (HHV-8), ebola virus (EBOV), arenaviruses (Tacaribe virus), poliovirus and HBV. 22 44 Therefore, ARB is considered as a potential compound to combat COVID-19. Later ARB (EC 50 =4. 11 1 μM, CC 50 =31.79 μM, SI=7.73) 23 was shown to inhibit COVID-19 infection (Fig. 3a ) more efficiently 2 and it interferes with the release of SARS-CoV-2 from intracellular vesicles (Fig. 3b) . Subsequently, 3 a retrospective study approved by the Third People's Hospital of Changzhou, China demonstrated 4 the efficacy of ARB monotherapy, which might be superior to LPV/r against COVID-19. 24 However, 5 the existing data with clinical trials is insufficient to precisely prove the effectiveness of ARB 6 against COVID-19 because of the limited sample size, and the unknown antiviral mechanisms. 7 Another study confirmed that ARB combined with LPV/r might benefit the patients by delaying 8 the progression of lung lesions and lowering the possibility of respiratory and gastrointestinal 9 transmissions. 25 Hence, a combination therapy could be the most effective way for managing 10 COVID-19, which needs to be validated in the near future. At present, phase IV clinical trials are 11 being carried out to test the efficacy of ARB against COVID-19 including NCT04350684 and 12 NCT04260594 ( Table 2 ). 13 14 DNA or RNA polymerase enzymes are essential components in the process of viral replication. 16 Nucleoside analogues are used to control the viral infections in clinics, which target the DNA or 17 RNA polymerase. Remdesivir (GS-5734), a prodrug developed by Gilead Science, is well 18 recognized as a potential antiviral drug against a wide array of infections with RNA viruses in cell 19 cultures, mice and non-human primate (NHP) models. The predicted mechanism of action is by 20 the incorporation of an active triphosphate into the viral RNA resulting in premature termination 21 of RNA synthesis that decreased the level of viral RNA (Fig. 1 ). 26 A study reported the efficacy of 22 Remdesvir (GS-5734), which is highly active against coronaviruses (EC 50 = 0.074±0.023 µM in 23 MERS-CoV-infected and EC 50 14 suggesting the feasibility of achieving 28 its working concentration in NHP models. Preliminary data showed that remdesivir has also 29 inhibited 2019-nCoV infection efficiently in a human cell line (human liver cancer Huh-7 cells). 30 The study also proved the anti-SARS-CoV-2 activity of GS-5734 using immunofluorescence 31 microscopy ( Fig. 2 ). 14 However, a report published in New England Journal of Medicine described 32 the effect of GS-5734 was still inadequate to assess in the first COVID-19 patient recovered after 33 remdesivir injection in the United States, because the viral load of the patient was decreased 34 before remdesivir was used. Hence, the patient recovery was attributable to the drug or the role 35 of self-defense mechanisms and supportive treatments was not made clear. 26 Currently, clinical 36 trials using GS-5734 as a therapeutic against 2019-nCoV infection are in progress (NCT04323761 37 and NCT04292899), and the effectiveness and adverse reactions of this drug are worthy of our 38 attention (Table 2 ). 39 40 Favipiravir (T-705), 6-Fluoro-3-hydroxypyrazine-2-carboxamide, is a novel RNA-dependent RNA 42 polymerase (RdRp) Inhibitor from Toyama Chemical Co., Ltd, and used to treat influenza viruses in 43 Japan. 28 Favipiravir-RTP (favipiravir ribofuranosyl-5'-triphosphate) is the active form of T-705 44 converted by host enzymes, which acts as a nucleotide analogue selectively inhibiting the RdRp. 1 At the same time, T-705 can also get incorporated into the nascent viral RNA resulting in 2 termination of the viral replication processes (Fig. 1) . 29 Since the catalytic domain of RdRp is 3 conserved among various types of RNA viruses, T-705 has a broad spectrum of anti-viral activities. 4 It has inhibited the replication of ZIKV in Vero cells (EC 50 = 3.5-3.8 µg/mL) and Zaire Ebola virus in 5 Vero E6 cells (EC 50 =10.5 µg/mL). 29 It is also used as a potential promising candidate for the 6 treatment of COVID-19. Favipiravir (EC 50 functions to alleviate excessive immune response and related-complications (Fig. 1) . 38 LH 43 inhibited the replication of 2019-nCoV with an IC 50 value of 411.2 μg/mL by CPE assay, and the 44 image of viral particles in ultra-thin sections of infected cells under electron microscopy 1 supported these observations (Fig. 4 ). 39 Another study tested the antiviral activity of LH against 2 2019-nCoV by CPE and plaque reduction assay using Vero E6 cells, and the results showed that LH 3 could inhibit the replication of 2019-nCoV and also reduce the production of pro-inflammatory 4 cytokines (TNF-α, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10). 39 Subsequently, a retrospective clinical 5 analysis on the treatment of SARS-CoV-2 with LH at the Ninth Hospital of Wuhan and CR＆WISCO 6 General Hospital was conducted andthe results showed that LH has significantly relieved the 7 cough and fever symptoms associated with the infection. 40 Similarly, QPD was also widely used 8 to treat SARS-CoV-2 in China. According to National Administration of Traditional Chinese 9 Medicine, the disease symptoms of patients were markedly stabilized with the disappearance of 10 cough and fever after QPD treatment. Recently, Researchers are focused to investigate and 11 analyse the potential protective mechanisms of QPD against SARS-CoV-2, the possible side effects 12 and new formulations. In the future, an integrated approach combining Chinese and Western 13 drugs will be tested to cure 2019-nCoV infected patients. 14 15 Convalescent plasma therapy (CPT) is a passive immune therapy used to fight the novel 18 coronavirus by injecting the plasma of the recovered person containing anti-virus antibodies. 41 It 19 has been successfully used for controlling SARS infection, but the limited quantity of the plasma 20 available impedes wider clinical applications. CPT was used to treat critically ill patients in 21 China, 42 and experts are still evaluating its efficacy and safety in clinical trials. Recently, it was 22 observed that after CPT therapy SARS-CoV-2 RNA has disappeared completely along with a clear 23 rise in neutralizing antibody titers in nearly all the patients, which could reduce mortality rate in 24 severe COVID-19 patients. 43 Interferons (IFNs) are a broad class of cytokines divided into type I, type II, and type III secreted 28 by the host when subjected to stress or infections, and also during the development of 29 autoinflammatory and autoimmune diseases. 44 Interferons are crucial for antiviral responses, 30 antigen presentation, development of autoimmunity and inflammation by activating the Jak-STAT 31 signaling pathway. 45 All IFNs share the ability to promote antiviral activities initiated by their 32 interactions with cognate receptors. 46 It's well known that type I IFNs could effectively inhibit 33 virus replication, and also show critical effects on the development and activation of immune cell 34 subsets. Given both the antiviral and immunomodulatory effects, type I IFNs are used either 35 alone or in combination with other medicines to treat a variety of chronic and acute viral 36 infections in clinics. 47 During the SARS-CoV and EBOV disease outbreak, Type I IFNs were used as 37 auxiliary drugs together with other antiviral medicines to alleviate patients' complications. 38 However, prolonged clinical use of IFNs is limited because of their adverse side effects including 39 neutropenia, thrombocytopenia, hyper-and hypothyroidism, pancreatitis, type I diabetes mellitus, 40 and irreversible pulmonary hypertension. 47 (Fig. 5A) . 52 This structure provides a model for discovering lead inhibitors to target COVID- 19 39 virus Mpro through computer-aided drug designs as well as virtual and high-throughput 40 screening methods, which is fundamental for identifying potential active molecules against 41 COVID-19. Subsequently, these authors developed a fluorescence resonance energy transfer 42 (FRET) assay to screen a library of ~10,000 compounds, and found 7 clinical drug candidates 43 including Ebselen (IC 50 = 0.67 μM), Disulfiram, Carmofur, Shikonin, Tideglusib, PX-12 and 44 TDZD-8. 52 Thus this study provided a reliable strategy for rapid drug discovery against COVID- 19 1 in the near future. Based on the structure of the substrate-binding pocket of SARS-CoV Mpro, 2 Hualiang Jiang and Hong Liu team have designed and synthesized novel inhibitors targeting the 3 SARS-CoV-2 Mpro and obtained compounds 11a ( compounds showed excellent inhibitory potency against SARS-CoV-2 Mpro enzyme. 53 The 6 pharmacokinetic properties of 11a and 11b demonstrate their good bioavailability with no 7 obvious toxicity. Their data indicated that these 2 compounds are good candidates for further 8 clinical studies (Fig. 5B, C) . Rolf Hilgenfeld and his team reported the x-ray structures of the 9 un-liganded SARS-CoV-2 Mpro and its complex with an α-ketoamide inhibitor. 54 Compound 11r is 10 a broad-spectrum inhibitor of main proteases, which could inhibit betacoronaviruses, 11 alphacoronaviruses as well as the 3CLpro of enteroviruses. They have optimized 11r and 12 synthesized the compounds 13a, 13b (Fig. 5D ) and 14b. All of them were tolerated well in mice. 13 More interestingly, compounds 13a and 13b tend to concentrate more in the lungs, which 14 implied the possibility of direct administration of these compounds to the lungs. This study 15 provided a solid framework for the development of pyridone-containing inhibitors against the 16 virus. Shuai Xia and his team have successfully solved the X-ray crystal structure of six-helical 17 bundle (6-HB) core of the HR1 and HR2 domains of the SARS-CoV-2 S protein S2 subunit, and 18 generated a series of lipopeptides derived from EK1 (a pan-coronavirus fusion inhibitor). It was 19 found that EK1C4 is the most potent fusion inhibitor available against SARS-CoV-2 S 20 protein-mediated membrane fusion and pseudovirus infection with IC50 of 1.3 and 15.8 nM, 21 respectively. 55 This suggests the possibility of using EK1C4 for prevention and treatment of 22 2019-nCoV infection. 23 24 At present the 2019-nCoV infection is rapidly spreading worldwide and as of 15 July 2020, the 26 death toll has reached 586,820. Hence, there is an urgent requirement to identify more effective 27 antiviral agents to combat the disease and validate their clinical effects. Although the 28 development of new drugs has shown some progress, currently, no specific treatment against 29 this new virus is available. Certainly, vaccines are the most effective tools to fight the viruses, and 30 many scientists all over the world are actively involved in developing specific vaccines. The phase 31 I clinical trial data of Ad5 vectored COVID-19 vaccine is promising and there is hope to defeat the 32 virus eventually. Considering the possible invalidity of vaccines because of the rapid gene 33 mutations in COVID-19, the chemical drugs and active molecules offer exciting opportunities. 34 China is one of the first-line countries in developing anti-epidemic strategies and, it has quickly 35 and efficiently controlled the domestic epidemic situation. Living conditions and production work 36 have gradually begun to get normalized to pre-COVID19 situation. For treating this virus infection, 37 many antiviral drugs were used in China, and this experience gained about beneficial strategies 38 and methods is being shared to other countries to contain the COVID-19 infection. Enormous 39 data generated is also facilitating further scientific studies in several laboratories. According to 40 the Diagnosis and Treatment Guidelines of 2019-nCoV in China (the seventh edition), 41 Lopinavir/ritonavir (combined with Ribavirin)，chloroquine and arbidol are recommended as 42 antiviral drugs for mild COVID-19 patients. In addition, IFN-α can be used as an adjuvant therapy 43 by inhalation. For severe patients, convalescent plasma therapy and blood purification treatment 44 are advisable. Tocilizumab is suitable to use for severely 2019-nCoV infected patients having 1 critical pulmonary lesions, especially with the increase of IL-6R expression. Chinese Traditional 2 medicines like Lianhuaqingwen capsules, Shufengjiedu capsules, Jinhuaqinggan granules and 3 Qingfeipaidu Decoction are also suggested to control the progression of disease. Although some 4 chemical drugs tested in vitro have shown anti-coronavirus effects, their potential remain to be 5 investigated in vivo. It is worth noting that more scientific research and reasonable design of 6 clinical trials are essential to assess the effectiveness of drugs. Some existing clinical reports are 7 lacking in their credibility because of the limitation in sample size. Researchers should design 8 scientific and logical experiments with reasonable sample size for clinical trials to evaluate the 9 accuracy of the results in the future. 10 11 As to the traditional therapy with chemical drugs, monotherapy may be inadequate to control 12 the virus, hence combination therapies should be considered seriously for combating COVID- 19 13 more efficiently. Different drug combinations and dosages as well as potential toxic effects are 14 worth exploring further. TCM also shows huge potential for alleviating and moderating the 15 symptoms of patients infected with 2019-nCoV. However, the composition of TCM is complex 16 and they also act on unknown targets. Hence, development of precise TCM prescriptions and 17 analysis of accompanied potential toxicities will be the major focus in future studies. 18 Furthermore, the crystal structure of COVID-19 virus Mpro provides a new and efficient strategy 19 to develop potential antiviral drugs that are based on computer-aided drug designs, virtual and 20 high-throughput screening in the near future, which could greatly speed up the drug 21 development processes. 22 Denver Ⅱ and Ⅲ Ⅱ and Ⅲ Galidesivir ( ( ( (BCX4430) ) ) ) NCT03891420 66 participants BioCryst Pharmaceuticals Ⅰ The colocalization of virions with early endosomes (EEs) or late endosomes (LEs) was analyzed by 5 immunofluorescence. Representative confocal microscopic images of virions (red) and LAMP1+ 6 ELs (green) in each group were shown. The nuclei (blue) were stained with Hoechst 33258 dye. Mpro-13b complex (PDB: 6Y2F) and the chemical structure of 13b. 9 Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China Clinical Characteristics of Coronavirus Disease 2019 in China Impact of heat-inactivation on the detection of SARS-CoV-2 IgM and IgG antibody by ELISA Deep learning for detecting corona virus disease 2019 (COVID-19) on high-resolution computed tomography: a pilot study Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2 Properties of Coronavirus and SARS-CoV-2 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Lopinavir/ritonavir: a review of its use in the management of HIV infection Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Is hydroxychloroquine beneficial for COVID-19 patients? Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes Arbidol as a broad-spectrum antiviral: an update Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Darunavir for the treatment of HIV infection The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China What has traditional Chinese medicine delivered for modern medicine Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS) Traditional Chinese medicine for COVID-19 treatment Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Retrospective Clinical Analysis on Treatment of Novel Coronavirus-infected Pneumonia with Traditional Chinese Medicine Lianhua Qingwen Convalescent plasma: new evidence for an old therapeutic tool? Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Convalescent plasma transfusion for the treatment of COVID-19: Systematic review COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons Interferon target-gene expression and epigenomic signatures in health and disease The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family Global virus outbreaks: Interferons as 1st responders Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection Recent Advances in Vaccine Technologies Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial Structure of Mpro from COVID-19 virus and discovery of its inhibitors Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion Drugs in clinic against 2019-nCoV were systematically collected and summarized. 2. Chemical drugs, Traditional Chinese Medicine, biological methods are presented. 3. The promising vaccine candidates against 2019-nCoV are described. 4. The mechanism, target The authors declare no conflict of interest.